Daily biotech intelligence: FDA actions, drug recalls, and recent research.
No FDA approval actions retrieved for this period.
SUN PHARMACEUTICAL INDUSTRIES INC [Class II] — 20260422 Product: Fluocinonide, USP, 0.05% Cream, 30g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Onta Reason: Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. [Class II] — 20260422 Product: MGC Health, Menthol- Cough Suppressant, Oral Anesthetic, Cough Drops, Honey Lemon, 30-count bag, Dis Reason: This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufac
Owen Biosciences Inc. [Class II] — 20260422 Product: FHF Farmhouse Fresh, Midnight Clearing, NIGHT LOTION, 2.5% BENZOYL PEROXIDE ACNE TREATMENT, OTC a) 0 Reason: Chemical contamination: Presence of benzene
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. [Class II] — 20260422 Product: MGC Health, Menthol- Cough Suppressant, Oral Anesthetic, Cough Drops, Sugar Free, Honey Lemon, 25-co Reason: This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufac
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. [Class II] — 20260422 Product: Discount Drug Mart Food Market, Cough Drops, Menthol -Cough Suppressant Anesthetic, 30-count bag, Di Reason: This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufac
Jinpai Zhao, Nishant Panda, Yen Ting Lin · 2026-05-01 · cs.CE · cs.LG
We introduce HyCOP, a modular framework that learns parametric PDE solution operators by composing simple modules (advection, diffusion, learned closures, boundary handling) in a query-conditioned way. Rather than learning a monolithic map, HyCOP learns a policy over short programs - which module to apply and for how long - conditioned on regime fe
Pavlin G. Poličar, Andraž Pevcin, Blaž Zupan · 2026-05-01 · cs.LG
Generating diverse, readable statistical charts from tabular data remains challenging for LLMs, as many failures become apparent after rendering and are not detectable from data or code alone. Existing chart datasets also rarely provide fully aligned artifacts, such as executable code, dataset context, and question-answer pairs. We present a struct
Arunabh Srivastava, Mohammad A., Khojastepour · 2026-05-01 · cs.LG · cs.CL
Humans solve problems by executing targeted plans, yet large language models (LLMs) remain unreliable for structured workflow execution. We propose RunAgent, a multi-agent plan execution platform that interprets natural-language plans while enforcing stepwise execution through constraints and rubrics. RunAgent bridges the expressiveness of natural
Xihao Chen, Yangyang Guo, Roger Zimmermann · 2026-05-01 · cs.CV · cs.AI
Key-Value (KV) cache has become a de facto component of modern Large Vision-Language Models (LVLMs) for inference. While it enhances decoding efficiency in Large Language Models (LLMs), its direct adoption in LVLMs introduces substantial GPU memory overhead due to the large number of vision tokens processed during the prefill stage. To tackle this
Stavros Orfanoudakis, Pedro P. Vergara · 2026-05-01 · cs.LG
While representation and similarity learning have improved the sample efficiency of Reinforcement Learning (RL), they are rarely used to shape policy updates directly in the action space. To bridge this gap, a geometry-aware RL algorithm that explicitly incorporates value-based similarity into the policy update, State-Action Value Geometry Optimiza
Jacques Raynal, Pierre Slangen, Jacques Margerit · 2026-05-01 · cs.LG · q-bio.NC
In biomechanical systems, observable performance is often used as a proxy for underlying system organization. However, this assumption implicitly presumes a correspondence between output metrics and internal system states that may not hold in adaptive systems. In this study, the vertical dimension of occlusion (VDO) is considered as a constraint ap
Shradha Sharma, Swapnil Dhamal, Shweta Jain · 2026-05-01 · cs.LG · cs.AI
We propose a new framework for meritocratic fairness in budgeted combinatorial multi-armed bandits with full-bandit feedback (BCMAB-FBF). Unlike semi-bandit feedback, the contribution of individual arms is not received in full-bandit feedback, making the setting significantly more challenging. To compute arm contributions in BCMAB-FBF, we first ext
Rodolphe Barlogis, Ferhat Tamssaouet, Quentin Falcoz · 2026-05-01 · cs.LG
This paper deals with solving the 2D Helmholtz equation on non-parametric domains, leveraging a physics-informed neural operator network based on the DeepONet framework. We consider a 2D square domain with an inclusion of arbitrary boundary geometry at its center. This inclusion acts as a scatterer for an incoming harmonic wave. The aim is to learn
STAT+: Biotech raises $42 million to run Huntington’s disease trial (STAT News) Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's disease.
Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies (STAT News) China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
Opinion: Are blue zones real? Answering that question is harder than ever (STAT News) "Blue zones" as a concept have strayed far and wide from their humble roots, write Shelley Wood and Eric Topol.
Immigration changes are driving foreign researchers to leave the U.S. — or not come to begin with (STAT News) Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering leaving early.
Federal appeals court blocks mailing of abortion pill mifepristone (STAT News) Mifepristone, involved in most abortions in the U.S., can now be distributed only in person and at clinics.
UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases (BioPharma Dive) The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.
What is your AI drug repurposing strategy missing? (BioPharma Dive) Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.
CBCT-based volumetric analysis of mandibular central incisors for age estimation in children and adolescents: a pilot study (Nature Health)
Assessment of particulate matter exposure levels and associated respiratory symptoms among oil seed processing factories workers (Nature Health)
Correlation analysis between morphological changes of lumbar core muscles and stages of femoral head necrosis (Nature Health)
Malnutrition by the GLIM criterion and reduced HGS are associated with anthropometric indicators in hospitalized patients (Nature Health)
This briefing is compiled automatically from FDA public APIs (openFDA), arXiv, and industry RSS feeds (STAT News, Fierce Biotech, BioPharma Dive, Nature, Science News). Not investment advice. Verify all data before making any decisions.